In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy.
In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy.
The combination of ibrutinib (Imbruvica) plus standard therapy with bendamustine (Treanda) and rituximab (Rituxan) significantly reduced the risk for disease progression or death by 80%
A subanalysis of the phase 3 clinical trial RESONATE showed that adherence to the recommended dose of ibrutinib in patients with chronic lymphocytic leukemia (CLL) who had received previous therapy improved extended progression-free survival (PFS) compared with patients who did not adhere to the treatment regimen.
Oncologists looking to learn about immunotherapy did not have to go very far at ASCO 2015. Many of the highest-impact presentations this year, including a plenary session, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
Combination treatment with the 2 immunotherapies nivolu­mab and ipilimumab led to a doubling in progression-free sur­vival (PFS) compared with ipilimumab alone in patients with advanced melanoma,
Oncology continues to be a top priority of utilization review, drug and cancer-type evaluation, and attempts at appropriate management for payers.
Page 4 of 4
Results 31 - 37 of 37
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME